Product Name | MCC-950 |
Description |
NLRP3 inflammasome activation inhibitor |
Purity | >98% (HPLC); NMR (conforms) |
CAS No. | 256373-96-3 |
Molecular Formula | C20H23N2O5S ∙ Na |
Molecular Weight | 426.5 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | May be dissolved in water (30 mg/ml): or DMSO (40 mg/ml) |
Source | Synthetic |
Appearance | White powder |
SMILES | COC1=CC=C(C=C1)CC(=O)NC2=CC(=CC=C2)O |
InChI | InChI=1S/C15H15NO3/c1-19-14-7-5-11(6-8-14)9-15(18)16-12-3-2-4-13(17)10-12/h2-8,10,17H,9H2,1H3,(H,16,18) |
InChIKey | OTXSEOHBMQFDBM-UHFFFAOYSA-N |
Safety Phrases |
Classification: Caution: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | MCC-950 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-604) |
Alternative Names | N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt; CRID3; CP-456773 sodium salt |
Research Areas | Cancer, Cell Signaling, Growth Factors, Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein, TNF |
PubChem ID | 1234617 |
Scientific Background | MCC-950 is a selective inhibitor of the NLRP3 inflammasome, a key mediator of neuroinflammation. It blocks both canonical and noncanonical NLRP3 activation, reducing IL-1β secretion and attenuating neuroinflammatory responses. MCC-950 has shown therapeutic potential in models of multiple sclerosis and Parkinson’s disease, where inflammasome activation contributes to neuronal damage and disease progression. Its ability to modulate innate immune signaling makes it a promising candidate for neurodegenerative disease research. |
References |
1. Laliberte R.E. et al. (2003) J. Biol. Chem. 278(19):16567-78. 2. Coll R.C., et al. (2011) PLoS One. 6(12):e29539. 3. Coll R.C., et al. (2015) Nat. Med. 21(3):248-255. 4. Kaneko N., et al. (2015) J. Immunol. Methods. 426:76-81. 5. Nguyen L., et al. (2022) J Parkinsons Dis. 12(7): 2117-2133. |
Reviews
There are no reviews yet.